Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression (EMBARC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01407094|
Recruitment Status : Completed
First Posted : August 1, 2011
Results First Posted : December 26, 2018
Last Update Posted : December 26, 2018
|Condition or disease||Intervention/treatment||Phase|
|Depression||Drug: Sertraline Drug: Placebo Drug: BupropionXL||Phase 2|
The current study is designed to identify biomarkers for the prediction of differential treatment outcomes between the SSRI antidepressant sertraline (SERT) and placebo (PBO) in a randomized trial for patients with MDD. In addition, a second stage will collect data to explore moderators and mediators of treatment outcomes between pharmacologically distinct active treatment arms: sertraline (SERT), a serotonergic antidepressant or bupropion (BUP), a nonserotonergic antidepressant. To reduce biologic heterogeneity, we will only enroll patients with early onset of DSM IV MDD (before age 30) because these criteria in probands have been shown to be associated with increased familial loading in families. Patients will also have recurrent MDD with 2 or more recurrences (including current episode). Additionally, patients will be required to have a current symptom severity score of 14 or more on the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR), both at study screening and at the randomization (baseline) visit. In the first stage, patients will receive an 8−week course of treatment in one of the two study arms. As part of the Sequential Multiple Assignment Randomized Trial (SMART) design patients that have not achieved a response at the end of 8 weeks to their stage one treatment, defined by < 50% improvement on the Clinical Global Improvement scale (CGI), will be switched to Stage 2 treatment (8 weeks). Patients who have achieved satisfactory response (>= 50% improvement on the CGI) will be continued on treatment for an additional 8 weeks.
Moderator Aims (Aim 1): To identify baseline clinical, neuroimaging, neurophysiological, and behavioral moderators of differential treatment outcome (mean symptom change and tolerability) for sertraline (SERT, a serotonergic antidepressant) versus placebo (PBO) for the treatment of MDD. Symptom change will be measured using the mean change from baseline in the 17-item Hamilton Rating Scale for Depression (HRSD17). Tolerability will be measured using the Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) and the Treatment Emergent Symptom Scale (TESS).
Mediator Aims (Aim 2): To identify early phase (week 1) changes in neuroimaging, neurophysiological, and behavioral tasks as mediators of differential treatment outcomes (symptom change, tolerability) to SERT and PBO.
Main Treatment Effects Aim (Aim 3): To compare the 8-week outcomes of SERT vs. PBO using mixed model regression analysis to maximize power to discriminate treatment efficacy differences.
- 17-item Hamilton Rating Scale for Depression (HRSD17)
- the Frequency, Intensity, and Burden Side Effects Rating (FIBSER)
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||296 participants|
|Intervention Model:||Sequential Assignment|
|Intervention Model Description:||
Patients were entered into Stage 1, treated with sertraline (Treatment A) or placebo (Treatment B), and used for the primary analysis which included the identification of potential mediators and moderators of response for these two treatments.
In stage two, responders to Treatment A remained on sertraline, and non-responders were switched to bupropion (Treatment C). Responders to Treatment B remained on placebo, and non-responders were switched to sertraline (Treatment D).
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC) for Depression|
|Actual Study Start Date :||July 29, 2011|
|Actual Primary Completion Date :||April 2016|
|Actual Study Completion Date :||April 2016|
Active Comparator: Sertraline
Other Name: Zoloft
Placebo Comparator: Placebo
1-4 pills per day
Active Comparator: Bupropion
Other Name: WelbutrinXL
- Hamilton Rating Scale for Depression [ Time Frame: Week 8 ]
The Hamilton Rating Scale for depression is a measure of depressive severity (HAM-D17; HDRS)
- Scores range from 0-52
- Lower scores indicate less depressive symptomatology, and so are the more desirable.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01407094
|United States, Massachusetts|
|Massachusetts General Hospital Boston|
|Boston, Massachusetts, United States, 02114|
|United States, Michigan|
|University of Michigan Ann Arbor|
|Ann Arbor, Michigan, United States, 48104|
|United States, New York|
|Columbia Univerisity New York City|
|New York, New York, United States, 10032|
|United States, Texas|
|UT Southwestern Medical Center Dallas|
|Dallas, Texas, United States, 75309|
|Principal Investigator:||Madhukar H Trivedi, M.D.||UT Southwestern Medical Center|
|Principal Investigator:||Patrick J McGrath, M.D.||Columbia University|
|Principal Investigator:||Myrna Weissman, Ph.D.||Columbia University|
|Principal Investigator:||Ramin Parsey, M.D.||Columbia University|
|Principal Investigator:||Maurizio Fava, M.D.||Massachusetts General Hospital|